Last reviewed · How we verify
METHAMPHETAMINE HYDROCHLORIDE
At a glance
| Generic name | METHAMPHETAMINE HYDROCHLORIDE |
|---|---|
| Modality | Small molecule |
| Phase | FDA-approved |
| First approval | 1943 |
Approved indications
Boxed warnings
- Methamphetamine has a high potential for abuse and misuse, which can lead to the development of a substance use disorder, including addiction. Misuse and abuse of CNS stimulants, including methamphetamine, can result in overdose and death [see Overdosage ( 10 )] , and this risk is increased with higher doses or unapproved methods of administration, such as snorting or injection. Before prescribing methamphetamine, assess each patient’s risk for abuse, misuse, and addiction. Educate patients and their families about these risks, proper storage of the drug, and proper disposal of any unused drug. Throughout methamphetamine treatment, reassess each patient’s risk of abuse, misuse, and addiction and frequently monitor for signs and symptoms of abuse, misuse, and addiction [see Warnings and Precautions ( 5.1 ) and Drug Abuse and Dependence ( 9.2 )] . WARNING: ABUSE, MISUSE, AND ADDICTION See full prescribing information for complete boxed warning. Methamphetamine has a high potential for abuse and misuse, which can lead to the development of a substance use disorder, including addiction. Misuse and abuse of CNS stimulants, including methamphetamine, can result in overdose and death. ( 5.1 , 9.2 , 10 ): • Before prescribing methamphetamine hydrochloride tablets, assess each patient’s risk for abuse, misuse, and addiction. • Educate patients and their families about these risks, proper storage of each drug, and proper disposal of any unused drug. • Throughout treatment, reassess each patient’s risk and frequently monitor for signs and symptoms of abuse, misuse, and addiction.
Common side effects
- Palpitation
- Dizziness
- Insomnia
- Tremor
- Headache
- Diarrhea
- Dryness of mouth
- Tachycardia
- Elevation of blood pressure
- Restlessness
- Overstimulation
- Euphoria
Serious adverse events
- Fatal cardiorespiratory arrest
- Psychotic episodes
- Myocardial infarction
- Sudden death
- Rhabdomyolysis
- Stevens-Johnson syndrome
- Toxic epidermal necrolysis
- Cardiomyopathy
- Anaphylaxis
- Angioedema
Key clinical trials
- Methamphetamine Isomer Pharmacology in Humans (PHASE1)
- Implementing a Contingency Management Program Addressing Methamphetamine Use For and With the People of Hawaii (NA)
- tTIS Targeted of the Striatum as an Intervention for MUD Patients (NA)
- Data2Action Oregon Project: Supporting Data-driven Decision-Making for Substance Use Services, Policy, and Overdose Prevention (NA)
- Reliability, Validity, and Acceptability of a Novel Visual Scale for Estimating Daily Methamphetamine Use Among People Who Use Methamphetamine
- ECG Findings in Methamphetamine Use
- Psychiatric Symptom Characteristics in Methamphetamine-Induced Psychosis With and Without Lifetime Cannabis Use
- Psychiatric Symptom Predictors in Methamphetamine-Induced Psychosis
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- METHAMPHETAMINE HYDROCHLORIDE CI brief — competitive landscape report
- METHAMPHETAMINE HYDROCHLORIDE updates RSS · CI watch RSS